Evidence map›Paper›PMID 41861817›Full record

ArticleStem cell reports2026

A humanized engineered heart tissue platform for cardiotoxicity assessment.

Yao-Hui Sun, Daphne A Diloretto, Hillary K J Kao, Padmini Sirish, Christophe Morisseau, Rasheed Sule, Ming-Fo Hsu, Regan L Smithers, James Overton, Valeriy Timofeyev and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Yao-Hui SunDivision of Cardiovascular Medicine, Department of Internal Medicine, School of Medicine, University of California, Davis, Sacramento, CA 95817, USA; Department of Radiation Oncology, University of California, Davis, Sacramento, CA 95817, USA. Electronic address: yhsun@health.ucdavis.edu.
Daphne A DilorettoDivision of Cardiovascular Medicine, Department of Internal Medicine, School of Medicine, University of California, Davis, Sacramento, CA 95817, USA.
Hillary K J KaoDivision of Cardiovascular Medicine, Department of Internal Medicine, School of Medicine, University of California, Davis, Sacramento, CA 95817, USA.
Padmini SirishDivision of Cardiovascular Medicine, Department of Internal Medicine, School of Medicine, University of California, Davis, Sacramento, CA 95817, USA.
Christophe MorisseauDepartment of Entomology and Nematology, and Comprehensive Cancer Center, University of California, Davis, Davis, CA 95616, USA.
Rasheed SuleDepartment of Neurobiology, Physiology, and Behavior, University of California, Davis, Davis, CA 95616, USA.
Ming-Fo HsuDepartment of Nutrition, University of California, Davis, Davis, CA 95616, USA.
Regan L SmithersDivision of Cardiovascular Medicine, Department of Internal Medicine, School of Medicine, University of California, Davis, Sacramento, CA 95817, USA.
James OvertonDivision of Cardiovascular Medicine, Department of Internal Medicine, School of Medicine, University of California, Davis, Sacramento, CA 95817, USA.
Valeriy TimofeyevDivision of Cardiovascular Medicine, Department of Internal Medicine, School of Medicine, University of California, Davis, Sacramento, CA 95817, USA.
Alexander MerleevDepartment of Dermatology, University of California, Davis, Sacramento, CA 95817, USA.
Gabriela GrigoreanDavis Genome Center, University of California, Davis, Davis, CA 95616, USA.
Brett S PhinneyDavis Genome Center, University of California, Davis, Davis, CA 95616, USA.
Emanual M MaverakisDepartment of Dermatology, University of California, Davis, Sacramento, CA 95817, USA.
Aldrin V GomesDepartment of Neurobiology, Physiology, and Behavior, University of California, Davis, Davis, CA 95616, USA.
Fawaz G HajDepartment of Nutrition, University of California, Davis, Davis, CA 95616, USA.
Jan A NoltaInstitute for Regenerative Cures and Stem Cell Program, University of California, Davis, Sacramento, CA 95817, USA.
James W ChanDepartment of Pathology and Laboratory Medicine, University of California, Davis, Sacramento, CA 95817, USA.
Bruce D HammockDepartment of Entomology and Nematology, and Comprehensive Cancer Center, University of California, Davis, Davis, CA 95616, USA.
Deborah K LieuDivision of Cardiovascular Medicine, Department of Internal Medicine, School of Medicine, University of California, Davis, Sacramento, CA 95817, USA.
Nipavan ChiamvimonvatDivision of Cardiovascular Medicine, Department of Internal Medicine, School of Medicine, University of California, Davis, Sacramento, CA 95817, USA; Department of Basic Medical Sciences, University of Arizona College of Medicine - Phoenix, Phoenix, AZ 85004, USA. Electronic address: nchiamvimonvat@arizona.edu.

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI KC KENT LLOYD · 2002 to 2026
$84.9M
Workshop on Environmental Technology Transfer and EntrepreneurshipP42ES004699 · NIEHS · UNIVERSITY OF CALIFORNIA DAVIS · PI YOUNG, THOMAS MICHAEL · 1987 to 2021
$50.1M
Functional Interactions of Cardiac Ion ChannelsR01HL085844 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CHIAMVIMONVAT, NIPAVAN · 2007 to 2025
$7.3M
Training Program In Basic & Translational Cardiovascular ScienceT32HL086350 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Martin Cadeiras, David A. Liem · 2008 to 2026
$7.1M
Supplement for bioactive lipids as effectors and indicators of the deleterious effects of human healthR35ES030443 · NIEHS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MORISSEAU, CHRISTOPHE HP · 2019 to 2025
$5.8M
Translational Study of Cardiac DysfunctionR01HL085727 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CHIAMVIMONVAT, NIPAVAN, SIRISH, PADMINI · 2008 to 2022
$5.7M
Targeting the genotype to phenotype link in HCM as a therapeutic strategyR01HL152055 · NHLBI · STANFORD UNIVERSITY · PI MERCOLA, MARK · 2021 to 2024
$2.3M
A prospective multiethnic HFpEF cohort from Californias Central ValleyU01HL160274 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Martin Cadeiras, Nipavan Chiamvimonvat · 2021 to 2026
$2.3M
Molecular Mechanisms of Atrial Fibrillation: A Multimodal AnalysisR01HL170520 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Nipavan Chiamvimonvat, Vladimir Filkov · 2024 to 2026
$1.8M
Forcing the sinoatrial node pacemaker functionR01HL159492 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Deborah K Lieu · 2023 to 2026
$1.6M
Hepatic protein-tyrosine phosphatase1B and alcoholic liver diseaseR21AA027633 · NIAAA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HSU, MING-FO · 2019 to 2020
$412k
Cardiac Regenerative Therapy Using Gene-Edited Stem Cells to Improve Transplantation OutcomesR56HL167932 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI SIRISH, PADMINI · 2023 to 2023
$400k
BLRD VA I01 BX000576CSRD VA I01 CX001490NCI NIH HHS P30 CA093373NHLBI NIH HHS F31 HL168956NHLBI NIH HHS R01 HL085727NHLBI NIH HHS R01 HL085844NHLBI NIH HHS R01 HL152055NHLBI NIH HHS R01 HL159492NHLBI NIH HHS R01 HL170520NHLBI NIH HHS R56 HL167932NHLBI NIH HHS T32 HL086350NHLBI NIH HHS U01 HL160274NIAAA NIH HHS R21 AA027633NIEHS NIH HHS P42 ES004699NIEHS NIH HHS R35 ES030443
6 · The paper itself

Abstract

Cardiovascular diseases (CVDs), many of which are influenced by exposure to environmental xenobiotics, lack physiologically relevant in vitro models for cardiotoxicity assessment. Although some pollutants have established associations with CVD, the effects of a wide range of potential toxicants remains unknown. Here, we developed a three-dimensional recellularized humanized engineered heart tissue (rHHT) platform by integrating decellularized human left ventricular extracellular matrix with human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), yielding spontaneously contracting tissues that recapitulate key features of native ventricular myocardium. We also generated a hiPSC line stably expressing the calcium indicator GCaMP6f, enabling real-time and longitudinal monitoring of calcium transients. Using ethanol and rotenone as examples, we demonstrate that the rHHT platform provides a sensitive system for evaluating cardiotoxicity and is more stringent than conventional monolayer approaches. This study presents a scalable platform for xenobiotic cardiotoxicity assessment, with potential applicability to high-throughput screening, mechanistic studies, and future personalized medicine applications.

Indexed as

CardiotoxicityHeartTissue EngineeringCalciumCell DifferentiationExtracellular MatrixHumansInduced Pluripotent Stem CellsMyocardiumMyocytes, CardiacCalciumcalcium transientcardiac tissue engineeringcardiotoxicitydrug screeningethanolextracellular matrixhuman induced pluripotent stem cell-derived cardiomyocyteshuman induced pluripotent stem cellsrotenone.xenobiotics

Identifiers

PMID41861817
PMCPMC13083795

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.